Tag: rch 01

November 22, 2017

RepliCel CEO: Anticipating the Approval of Their Dermal Injector, its Impact in Europe and Beyond

As RepliCel prepares for a potentially major year in their business development, their CEO Lee Buckler discusses with the Investing...
June 13, 2017

RepliCel Enters Collaboration with University of British Columbia

RepliCel Life Sciences signed a collaborative research project agreement with the University of British Columbia.
April 4, 2017

RepliCel Shows New Data On Study Of RCS-01

RepliCel Life Sciences (OTCQB: REPCF, TSXV:RP) announced positive data for interim analysis of a Phase I study of RCS-01 to...
March 1, 2017

RepliCel's Electronic Injector One Step Closer To Market

After signing a new deal with two new key partners RepliCel Life Sciences is getting ready to launch its RCI-02...
February 28, 2017

RepliCel Life Sciences Partners with European Firms to Develop Final Prototype of its Dermal Injector

RepliCel Life Sciences (OTCQB:REPCF) announced it signed agreements with two companies in Europe in order to begin testing and manufacturing...
January 5, 2017

RepliCel CEO Provides 2017 Forecast

RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSX VENTURE:RP) (“RepliCel” or the “Company”), a clinical-stage regenerative medicine company developing unique biologic products...
September 27, 2016

RepliCel Provides Update on Shiseido License and Co-Development for RCH-01

RepliCel Life Sciences, a clinical-stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to provide...